Tower Research Capital LLC (Trc) Rubius Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$0.14 - $0.31 $2,313 - $5,122	-16,523 Reduced 99.85%	25 $0
Q3 2022 Nov 10, 2022	BUY	$0.46 - $1.29 $711 - $1,994	1,546 Added 10.31%	16,548 $7,000
Q2 2022 Aug 15, 2022	BUY	$0.79 - $5.98 $11,261 - $85,244	14,255 Added 1908.3%	15,002 $13,000
Q1 2022 May 12, 2022	SELL	$4.25 - $10.4 $36,847 - $90,168	-8,670 Reduced 92.07%	747 $4,000
Q4 2021 Feb 14, 2022	SELL	$9.68 - $17.74 $851 - $1,561	-88 Reduced 0.93%	9,417 $92,000
Q3 2021 Nov 15, 2021	BUY	$17.6 - $25.91 $104,684 - $154,112	5,948 Added 167.22%	9,505 $170,000
Q2 2021 Aug 16, 2021	BUY	$22.26 - $28.43 $5,676 - $7,249	255 Added 7.72%	3,557 $87,000
Q1 2021 May 17, 2021	SELL	$8.02 - $32.01 $4,338 - $17,317	-541 Reduced 14.08%	3,302 $87,000
Q4 2020 Feb 16, 2021	SELL	$4.23 - $8.73 $129,002 - $266,238	-30,497 Reduced 88.81%	3,843 $29,000
Q3 2020 Nov 16, 2020	BUY	$4.65 - $6.25 $114,748 - $154,231	24,677 Added 255.38%	34,340 $172,000
Q2 2020 Aug 13, 2020	BUY	$4.01 - $6.88 $36,390 - $62,436	9,075 Added 1543.37%	9,663 $58,000
Q1 2020 May 15, 2020	SELL	$3.74 - $9.84 $22,941 - $60,358	-6,134 Reduced 91.25%	588 $3,000
Q4 2019 Feb 07, 2020	BUY	$7.23 - $14.12 $42,121 - $82,263	5,826 Added 650.22%	6,722 $64,000
Q3 2019 Nov 05, 2019	SELL	$7.85 - $15.75 $26,548 - $53,266	-3,382 Reduced 79.06%	896 $7,000
Q2 2019 Aug 13, 2019	BUY	$13.5 - $19.94 $57,753 - $85,303	4,278 New	4,278 $67,000
Q1 2019 May 14, 2019	SELL	$13.27 - $18.51 $18,272 - $25,488	-1,377 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$13.83 - $22.97 $19,043 - $31,629	1,377 New	1,377 $22,000

325

Ticker RUBY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,357,000
Description
Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatmen...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.